Reckitt Benckiser Receives Hart-Scott-Rodino Antitrust Clearance for Acquisition of Adams Respiratory Therapeutics
08 Enero 2008 - 6:00AM
PR Newswire (US)
SLOUGH, U.K. and CHESTER, N.J., Jan. 8 /PRNewswire-FirstCall/ --
Reckitt Benckiser Group plc (RB.L) ("Reckitt Benckiser") and Adams
Respiratory Therapeutics, Inc. (NASDAQ:ARxT) ("Adams") announced
today that they have received early termination of the waiting
period under the Hart-Scott-Rodino Antitrust Improvements Act of
1976 (HSR) relating to the previously announced tender offer to
purchase all of the outstanding shares of common stock of Adams.
Reckitt Benckiser initiated, through its wholly owned subsidiary
Twickenham Inc., a cash tender offer on December 21, 2007, to
purchase all outstanding shares of common stock of Adams for
US$60.00 per share. The tender offer will expire at 12:00 midnight,
New York City time, on January 23, 2008, unless extended in
accordance with the Merger Agreement entered into between Reckitt
Benckiser, Twickenham and Adams and the applicable rules and
regulations of the U.S. Securities and Exchange Commission (SEC).
The offer remains subject to other customary conditions, including
the acquisition by Twickenham of a majority of Adams' shares of
common stock on a fully diluted basis. Important Information This
announcement is neither an offer to purchase nor a solicitation of
an offer to sell securities. The tender offer is being made
pursuant to a tender offer statement filed with the SEC on Schedule
TO (including an offer to purchase, a related letter of transmittal
and other offer documents) and the related
solicitation/recommendation statement filed with the SEC on
Schedule 14D-9, which contain important information that should be
read carefully before any decision is made with respect to the
tender offer. Those materials (and all other offer documents filed
with the SEC) are available at no charge on the SEC's Web site:
http://www.sec.gov/. Notes for Editors Reckitt Benckiser is a world
leader in household cleaning, health and personal care. The Company
is truly global, with over 60 operating companies and some 43
manufacturing facilities worldwide and has sales in 180 countries.
Reckitt Benckiser employs 22,000 people around the world. Amongst
the Company's leading brands in household are Lysol, the world
leader in disinfecting cleaning, Calgonit & Finish &
Electrasol, the world leaders in automatic dishwashing, Woolite,
world leader in fine fabrics, Vanish & Spray'nWash, world
leaders in fabric treatment, Airwick and Mortein, both No.2 brands
in air care and pest control respectively. In Health & Personal
Care (25% of net revenues), leading brand positions include Veet,
the world number one depilatory and Dettol the world's leading
antiseptic, Nurofen, the leading European analgesic, Strepsils,
world number one in medicated sore throat, Gaviscon the No.1 gastro
intestinal remedy in UK and Lemsip the UK no.1 in cold/flu
remedies. Reckitt Benckiser is headquartered in Slough just outside
London, UK and is listed on the London stock exchange. With a
market capitalization of c.20bn pounds sterling it ranks among the
top 25 UK listed companies. Reckitt Benckiser had net revenues of
4.92bn pounds, operating profit of 910m pounds, and net income of
674m pounds in 2006. About Adams Respiratory Therapeutics, Inc.
Adams is a specialty pharmaceutical company focused on the
late-stage development, commercialization and marketing of
over-the-counter and prescription pharmaceuticals for the treatment
of respiratory disorders. DATASOURCE: Adams Respiratory
Therapeutics, Inc. CONTACT: Mark Wilson, Corporate Controller and
Investor Relations Manager (Investor Queries), or Fiona Fong, Head
of Corporate Communications (Press Queries), both of Reckitt
Benckiser, +44-1753-217-800; or PR Agency, Susan Gilchrist of
Brunswick, +44-207-404-5959, or Cindy Leggett Flynn of Brunswick
New York, +1-212-333-3810; or Janet M. Barth, SVP Investor
Relations & Corporate Communications, +1-908-879-2428, or Faith
Pomeroy-Ward, Sr. Manager Investor Relations & Corporate
Communications, +1-908-879-1418, both of Adams Respiratory
Therapeutics Web site: http://www.adamsrt.com/
Copyright